Status:
NOT_YET_RECRUITING
RCT: Suzetrigine vs Norco for Post-op Pain
Lead Sponsor:
Jacob Lensing
Conditions:
Pain Control
Eligibility:
All Genders
18-45 years
Phase:
PHASE4
Brief Summary
Journavx (suzetrigine) is a novel non-opioid analgesic that is FDA approved for acute pain management and may offer a promising alternative for managing postoperative pain. Suzetrigine is selective in...
Detailed Description
Every year millions of oral and maxillofacial surgical procedures are performed globally, with patients frequently experiencing significant postoperative pain that can persist long after hospital disc...
Eligibility Criteria
Inclusion
- Patients aged 18-45 years requiring extraction of impacted mandibular bilateral third molar teeth, uncomplicated mesioangular impacted teeth, or vertical impaction of unerupted and impacted mandibular third molars.
- Patients aged 18-45 years undergoing bimaxillary orthognathic surgery.
Exclusion
- Pregnant or nursing, history of prior opioid abuse, have history of temporomandibular dysfunction or local myofascial pain disorder preoperatively, with history of congenital syndrome requiring previous surgeries, orthognathic revisions, have a bleeding disorder, cannot receive instruction in English, are currently utilizing analgesics for another painful condition
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2026
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT07195669
Start Date
October 1 2025
End Date
January 30 2026
Last Update
September 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LSU Dental School
New Orleans, Louisiana, United States, 70214